119 Results

Valeant Pharmaceuticals International announces marketing information for Siliq (brodalumab), a new treatment for psoriasis.

 Added 16 hours ago

Valeant Pharmaceuticals International, Inc. announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the...

The XII International Society of Dermatology kicks off congress in Buenos Aires, Argentina

 Added 4 days ago

Congress President Ricardo Galimberti opens proceedings to over 6,000 delegates.

UK NICE gives final appraisal recommending use of Cosentyx (secukinumab) in psoriatic arthritis- Novartis

 Added 4 days ago

The UK's National Institute for Health and Care Excellence has published its final appraisal which backs the use of Cosentyx...

Positive Phase III REVIVE-1 study of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).- Motif Bio.

 Added 4 days ago

Motif Bio plc announced positive topline results from REVIVE-1, a global Phase III clinical trial of its investigational drug candidate...

FDA issues Complete Response Letter for TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia.- Therapeutics MD Inc.

 Added 12 days ago

Therapeutics MD, Inc. announced that the Company received a letter from the FDA stating that, as part of the FDA’s...

Phase IV study results for Restylane dermal fillers indicate benefits in facial expressions- Galderma

 Added 17 days ago

Galderma announced the results from two Phase IV clinical studies of its most recent additions to the Restylane family of...

FDA grants accelerated approval for Bavencio (avelumab)to treat Merkel cell carcinoma .-Merck KgAA + Pfizer

 Added 30 days ago

Merck and Pfizer Inc. announced that the FDA has approved Bavencio (avelumab) Injection 20 mg/mL, for intravenous use, for the...

Successful Phase III trial of Ameluz (5-aminolevulinic acid) with photodynamic therapy to treat actinic keratosis.- Biofrontera AG

 Added 1 month ago

Biofrontera AG announced detailed results from its Phase III clinical trial evaluating the safety and efficacy of its topical prescription...

New data from Novartis suggests that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.

 Added 1 month ago

Novartis has announced new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis...

Array BioPharma Inc.,withdraws from the FDA, binimetinib monotherapy for the treatment of NRAS-mutant melanoma.

 Added 1 month ago

Array BioPharma Inc. announced that it has withdrawn from the FDA Division of Oncology Products its new drug application (NDA)...

Load more